Abidjan, Ivory Coast
Abidjan, Ivory Coast

Time filter

Source Type

Adlhoch C.,Robert Koch Institute | Kaiser M.,GenExpress GmbH | Loewa A.,Robert Koch Institute | Ulrich M.,Robert Koch Institute | And 9 more authors.
Emerging Infectious Diseases | Year: 2012

During 2010-2011, we investigated interspecies transmission of partetraviruses between predators (humans and chimpanzees) and their prey (colobus monkeys) in Côte d'Ivoire. Despite widespread infection in all species investigated, no interspecies transmission could be detected by PCR and genome analysis. All sequences identified formed species- or subspecies (chimpanzee)-specific clusters, which supports a co-evolution hypothesis.


Toure O.A.,Institute Pasteur Cote dIvoire | Valecha N.,National Institute of Malaria Research | Tshefu A.K.,University of Kinshasa | Thompson R.,National Health Research Institute | And 30 more authors.
Clinical Infectious Diseases | Year: 2016

Background. Artemisinins, which are derived from plants, are subject to risk of supply interruption due to climatic changes. Consequently, an effort to identify a new synthetic antimalarial was initiated. A fixed-dose combination of arterolane maleate (AM), a new synthetic trioxolane, with piperaquine phosphate (PQP), a long half-life bisquinoline, was evaluated in patients with uncomplicated Plasmodium falciparum malaria. Methods. In this multicenter, randomized, double-blind, comparative, parallel-group trial, 1072 patients aged 12-65 years with P. falciparum monoinfection received either AM-PQP (714 patients) once daily or artemether-lumefantrine (A-L; 358 patients) twice daily for 3 days. All patients were followed up until day 42. Results. Of the 714 patients in the AM-PQP group, 638 (89.4%) completed the study; of the 358 patients in the A-L group, 301(84.1%) completed the study. In both groups, the polymerase chain reaction corrected adequate clinical and parasitological response (PCR-corrected ACPR) on day 28 in intent-to-treat (ITT) and per-protocol (PP) populations was 92.86% and 92.46% and 99.25% and 99.07%, respectively. The corresponding figures on day 42 in the ITT and PP populations were 90.48% and 91.34%, respectively. After adjusting for survival ITT, the PCR-corrected ACPR on day 42 was >98% in both groups. The overall incidence of adverse events was comparable. Conclusions. AM-PQP showed comparable efficacy and safety to A-L in the treatment of uncomplicated P. falciparum malaria in adolescent and adult patients. AM-PQP demonstrated high clinical and parasitological response rates as well as rapid parasite clearance. © 2016 The Author. All rights reserved.


PubMed | University of Science, Medical Affairs & Clinical Research, Government Wenlock District Hospital, Clinical Pharmacology & Pharmacokinetics. and 13 more.
Type: Journal Article | Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | Year: 2016

Artemisinins, which are derived from plants, are subject to risk of supply interruption due to climatic changes. Consequently, an effort to identify a new synthetic antimalarial was initiated. A fixed-dose combination of arterolane maleate (AM), a new synthetic trioxolane, with piperaquine phosphate (PQP), a long half-life bisquinoline, was evaluated in patients with uncomplicatedPlasmodium falciparummalaria.In this multicenter, randomized, double-blind, comparative, parallel-group trial, 1072 patients aged 12-65 years withP. falciparummonoinfection received either AM-PQP (714 patients) once daily or artemether-lumefantrine (A-L; 358 patients) twice daily for 3 days. All patients were followed up until day 42.Of the 714 patients in the AM-PQP group, 638 (89.4%) completed the study; of the 358 patients in the A-L group, 301(84.1%) completed the study. In both groups, the polymerase chain reaction corrected adequate clinical and parasitological response (PCR-corrected ACPR) on day 28 in intent-to-treat (ITT) and per-protocol (PP) populations was 92.86% and 92.46% and 99.25% and 99.07%, respectively. The corresponding figures on day 42 in the ITT and PP populations were 90.48% and 91.34%, respectively. After adjusting for survival ITT, the PCR-corrected ACPR on day 42 was >98% in both groups. The overall incidence of adverse events was comparable.AM-PQP showed comparable efficacy and safety to A-L in the treatment of uncomplicatedP. falciparummalaria in adolescent and adult patients. AM-PQP demonstrated high clinical and parasitological response rates as well as rapid parasite clearance.India. CTRI/2009/091/000101.


Scuda N.,Robert Koch Institute | Madinda N.F.,Robert Koch Institute | Madinda N.F.,Max Planck Institute for Evolutionary Anthropology | Akoua-Koffi C.,University Teaching Hospital Bouake | And 15 more authors.
PLoS Pathogens | Year: 2013

Polyomaviruses are a family of small non-enveloped DNA viruses that encode oncogenes and have been associated, to greater or lesser extent, with human disease and cancer. Currently, twelve polyomaviruses are known to circulate within the human population. To further examine the diversity of human polyomaviruses, we have utilized a combinatorial approach comprised of initial degenerate primer-based PCR identification and phylogenetic analysis of nonhuman primate (NHP) polyomavirus species, followed by polyomavirus-specific serological analysis of human sera. Using this approach we identified twenty novel NHP polyomaviruses: nine in great apes (six in chimpanzees, two in gorillas and one in orangutan), five in Old World monkeys and six in New World monkeys. Phylogenetic analysis indicated that only four of the nine chimpanzee polyomaviruses (six novel and three previously identified) had known close human counterparts. To determine whether the remaining chimpanzee polyomaviruses had potential human counterparts, the major viral capsid proteins (VP1) of four chimpanzee polyomaviruses were expressed in E. coli for use as antigens in enzyme-linked immunoassay (ELISA). Human serum/plasma samples from both Côte d'Ivoire and Germany showed frequent seropositivity for the four viruses. Antibody pre-adsorption-based ELISA excluded the possibility that reactivities resulted from binding to known human polyomaviruses. Together, these results support the existence of additional polyomaviruses circulating within the human population that are genetically and serologically related to existing chimpanzee polyomaviruses. © 2013 Scuda et al.


Ngazoa-Kakou E.S.,Laval University | Ekaza E.,Institute Pasteur Cote dIvoire | Aka N.,Institute Pasteur Cote dIvoire | Coulibaly-N'Golo D.,Institute Pasteur Cote dIvoire | And 2 more authors.
African Journal of Microbiology Research | Year: 2011

Buruli ulcer (BU) is caused by a mycobacterium called Mycobacterium ulcerans. The events of BU are the skin lesions. The lack of early diagnosis and treatment cause severe disability. Today the emergence to BU in Africa and particularly in Côte d'Ivoire needs faster diagnosis to control and to prevent the infection by M. ulcerans. The surveillance of BU is difficult, because the transmission of M. ulcerans occurs in rural regions where the transport of fresh collected sample is long, and the detection with culture technique needs several months. This study has allowed the application of polymerase chain reaction (PCR) technique in real time with two targets for molecular diagnosis of BU in Côte d'Ivoire. 63 samples (clinical, environmental, local strains and reference strains) were analyzed in realtime PCR by comparing the target of the Insertion Sequence (IS) 2404 and the sequence KetoreductaseB (KR-B), located respectively on the chromosome and on the virulence plasmid. 49 samples (76%) were positive in real-time for both targets. The sensitivity of the PCR shows a detection limit of 0.25 genome copy for both targets. The capacity, speed and sensitivity of real-time PCR assays improve the diagnosis and contribute to strengthening the eradication of BU in Côte d'Ivoire. © 2011 Academic Journals.

Loading Institute Pasteur Cote dIvoire collaborators
Loading Institute Pasteur Cote dIvoire collaborators